Loading...
OTCM
ENZC
, Last price  
USD
Name

Enzolytics Inc

Chart & performance

D1W1MN
OTCM:ENZC chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
29.13%
Rev. 5Y
60.22%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
05,68714,70836,96852,80700000190,0005,00000200,000052,79600
Net income
-92k
L-76.59%
-421,617-425,948-969,788-7,513,915-882,928-965,483-170,000-1,077,000-5,048,000-549,592-57,282-1,758,000920,429-3,481,000-669,000-2,941,000-2,176,832-394,000-92,239
CFO
-563k
L-36.02%
40,227-130,969-371,366-409,94514,675-453,7764,886,161-3,243,339-2,240-491,014-1,306,388-2,660,790-880,077-563,040

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary cell line, specifically engineered to produce human monoclonal antibodies that effectively target and neutralize the human immunodeficiency virus (HIV).
IPO date
Dec 29, 2008
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT